Joint venture buyout to strengthen GSK's China vaccines presence
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is widening its footprint in China's vaccines market by acquiring all of the shares in a joint venture for influenza vaccines set up with a local partner two years ago.